Table 3. . Hsp90 trials in oncogene-addicted NSCLC.

Drug name	Study name or ClinicalTrials.gov identifier	Phase	Patient population	Treatment arm(s)	Status	Ref.
IPI-504	NCT00431015	II	Advanced NSCLC	IPI-504	Completed	[90,91]
Ganetespib (STA-9090)	NCT02192541	I	Pretreated solid tumors (included advanced nonsquamous NSCLC)	Ganetespib and Ziv-aflibercept	Completed	[92–94]
	NCT01031225	II	Genotypically defined advanced NSCLC	Ganetespib	Completed
	CHIARA (NCT01562015)	II	ALK+ advanced NSCLC	Ganetespib	Completed
	NCT01579994	II	ALK+ crizotinib-naive advanced NSCLC	Ganetespib and crizotinib	Ongoing but not recruiting
	GALAXY trial (NCT01348126)	II/III	Advanced NSCLC	Ganetespib in combination with docetaxel versus docetaxel alone	Terminated for futility
	GALAXY-2 (NCT01798485)	III
AUY922	NCT01772797	Ib	ALK+ advanced NSCLC pretreated with crizotinib	Dose escalation study of LDK378 and AUY922	Ongoing but not recruiting	[95–97]
	NCT01752400	II	ALK+ advanced NSCLC pretreated with crizotinib	AUY922	Ongoing but not recruiting
	NCT01124864	II	Advanced NSCLC progressed after two lines of prior chemotherapy	AUY922	Completed
	NCT01922583	II	Advanced NSCLC with molecular alterations other than EGFR+, progressed after one line of systemic therapy	AUY922	Recruiting
	NCT01854034	II	NSCLC with exon 20 insertion mutations in EGFR	AUY922	Recruiting
	NCT01646125	II	Advanced EGFR+ NSCLC, progressed on prior EGFR-TKI treatment	AUY922 vs pemetrexed or docetaxel	Completed
	NCT01259089	I/II	Advanced EGFR+ NSCLC progressed on prior eErlotinib	AUY922 and erlotinib	Completed
AT13387	NCT01712217	I/II	Advanced ALK+ NSCLC pretreated with crizotinib	AUY922 alone (I) and with critotinib (II)	Ongoing but not recruiting	[98]